Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041)
European Journal of Cancer · 2023
DOI: 10.1016/j.ejca.2023.01.001 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Peter A Fasching und 15 weiteren Autor:innen. Beteiligte Einrichtung: Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlan…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany. Electronic address: peter.fasching@fau.de.
- Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany.
- Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop, Germany.
- Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Germany; Biostatistics Unit, Department of Gynecology a…
- ClinSol GmbH & Co KG, Würzburg, Germany.
- Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Germany.
Zitieren
APA
Fasching, P. A., Hein, A., Kolberg, H. C., Häberle, L., Uhrig, S., Rübner, M., Belleville, E., Hack, C. C., Fehm, T. N., Janni, W., Hartmann, A., Erber, R., Theuser, A. K., Brucker, S. Y., Hartkopf, A. D., & Untch, M. (2023). Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.01.001
Vancouver
Fasching PA, Hein A, Kolberg HC, Häberle L, Uhrig S, Rübner M, et al. Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041). European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.01.001
BibTeX
@article{Fasching2023,
author = {Fasching, Peter A and Hein, Alexander and Kolberg, Hans-Christian and Häberle, Lothar and Uhrig, Sabrina and Rübner, Matthias and Belleville, Erik and Hack, Carolin C and Fehm, Tanja N and Janni, Wolfang and Hartmann, Arndt and Erber, Ramona and Theuser, Anna-Katharin and Brucker, Sara Y and Hartkopf, Andreas D and Untch, Michael},
title = {Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer – A single-arm phase II trial (NeoImmunoboost, AGO-B-041)},
journal = {European Journal of Cancer},
year = {2023},
doi = {10.1016/j.ejca.2023.01.001}
}
EUVIMED